Clinical Trials Browser

Phase 2 × montanide ISA 51 × 90 days × Clear all

NCT07169617 2026-03-19

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Phase 2 Not yet recruiting

Lung Neoplasms

NCT02455557 2026-02-25

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Active not recruiting

66 enrolled 11 charts

Glioblastoma, Gliosarcoma